{"entity":{"id":"biomarker-qualification-context","kind":"term","name":"Biomarker qualification and context of use","aka":["biomarker context of use","FDA biomarker qualification"],"tldr":"A biomarker can be accepted for a specified role in drug development. That acceptance has a defined scope and does not approve every test that measures it.","summary":"FDA biomarker qualification concerns a specified interpretation and context of use in medical product development. The agency explicitly distinguishes qualification of the biomarker from qualification of its measurement method. The biomarker, specimen source, measurable characteristic and analytic method belong in a complete description. A qualification claim should retain that scope rather than being treated as general diagnostic approval or proof of clinical utility for every use.","asOf":"2026-11-08","links":[{"label":"FDA: biomarkers, roles and qualification","url":"https://www.fda.gov/drugs/biomarker-qualification-program/about-biomarkers-and-qualification"}],"tags":[],"related":["biomarker","analytical-vs-clinical-validation"],"cancers":[],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"category":"Regulation & policy"},"route":"/terms/biomarker-qualification-context/","neighbours":{"term":[{"id":"analytical-vs-clinical-validation","kind":"term","name":"Analytical versus clinical validation","route":"/terms/analytical-vs-clinical-validation/"},{"id":"biomarker","kind":"term","name":"Biomarker","route":"/terms/biomarker/"},{"id":"measurement-to-benefit-evidence","kind":"term","name":"Evidence from measurement to patient benefit","route":"/terms/measurement-to-benefit-evidence/"}]}}